Insider Buying: Hemab Therapeutics (NASDAQ:COAG) Major Shareholder Acquires $159,036.30 in Stock

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) major shareholder Ra Capital Management, L.P. acquired 6,387 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 12th. The stock was purchased at an average cost of $24.90 per share, for a total transaction of $159,036.30. Following the completion of the purchase, the insider owned 6,372,170 shares in the company, valued at approximately $158,667,033. The trade was a 0.10% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ra Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 11th, Ra Capital Management, L.P. acquired 39,869 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.81 per share, for a total transaction of $989,149.89.
• On Friday, May 8th, Ra Capital Management, L.P. acquired 1,483 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.98 per share, for a total transaction of $37,045.34.
• On Thursday, May 7th, Ra Capital Management, L.P. acquired 9,906 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.46 per share, for a total transaction of $242,300.76.
• On Wednesday, May 6th, Ra Capital Management, L.P. acquired 68,018 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.60 per share, for a total transaction of $1,673,242.80.
• On Tuesday, May 5th, Ra Capital Management, L.P. acquired 97,411 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $24.63 per share, for a total transaction of $2,399,232.93.
• On Monday, May 4th, Ra Capital Management, L.P. acquired 2,675,000 shares of Hemab Therapeutics stock. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $48,150,000.00.

Hemab Therapeutics Stock Down 1.1%

NASDAQ:COAG opened at $28.07 on Friday. Hemab Therapeutics Holdings, Inc. has a 52 week low of $23.00 and a 52 week high of $36.61.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.